ImmunoPrecise Antibodies Ltd.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (IPA) is a biotherapeutic intelligence company focused on antibody discovery and development. Through its HUB of Biotherapeutic Intelligence™ platform, IPA combines in vitro, in vivo, and in silico approaches to solve complex challenges in biotherapeutic science, aiming to lead pharmaceutical partners into the era of the antibody with cutting-edge technologies and expertise.

Products & Services

Antibody Discovery Services:Comprehensive services including target analysis, immunization, antibody discovery and characterization, developability profiling, optimization, engineering, and preclinical services.

Protein Production:Custom protein production with high purity and efficiency, including the rPEx(r) production program, and an extensive catalog of protein products like organoid growth factors.

AI Technology (LENSai™):Innovative AI-driven solutions for biotherapeutic research, featuring applications like Immunogenicity Screening and tools to transform data into meaningful insights with high accuracy.

Online Store:Offers a catalog of protein products, including exclusive WNT Surrogate-Fc fusion proteins and RSPO proteins, with special offers for new users.

Specialties

Antibody Discovery Protein Production AI-Driven Biotherapeutic Research Cancer Therapeutics Immunogenicity Screening

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: At-the-Market Equity Offering T: - FT: At-the-Market Equity Offering	A: 7000000 MR: - FA: USD $7.0 million FAN: 7000000	D: 2025-01-27 FD: 2025-01-27	1 investors
2	RT: Convertible Debentures T: - FT: Convertible Debentures	A: 3000000 MR: - FA: $3.0 million FAN: 3000000	D: 2024-07-16 FD: 2024-07-16	2 investors
3	RT: Public Offering of Common Shares T: - FT: Public Offering of Common Shares	A: 1265000 MR: - FA: $1.265 million FAN: 1265000	D: 2023-12-08 FD: 2023-12-08	2 investors

At-the-Market Equity Offering Latest

2025-01-27

$7.0M

1 investor (Pro only)

Convertible Debentures 2024-07-16

$3.0M

Public Offering of Common Shares 2023-12-08

$1.3M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jennifer Bath

Authorized Representative

LinkedIn (Pro only)

I

Ilse Roodink

Authorized Representative

I

Ingrid Brands

Chief Innovation and Strategy Officer

LinkedIn (Pro only)

J

Joseph Scheffler

Interim Chief Financial Officer

D

Dirk Van Hyfte

Chief Technology Officer

F

Frédéric Chabot

Head of Corporate Development

View 13 more team members with Pro

Unlock Full Team Directory

Recent News